Unfortunately with the recent Pharmasset (VRUS) buyout announcement, Gilead has strayed from the plan of rewarding investors with capital returns toward buying growth. Typically these deals don't workout for investors of the purchasing company.
With the reporting of Q4 numbers, Gilead verified on the conference call that stock purchases have all but been eliminated as the company raised debt to buy Pharmasset.
Via Seeking Alpha transcript:
Robin L. WashingtonAnd, Geoff, relative to your share count, as we talked about with the acquisition, we did moderate and pretty much have spent our share repurchases after October of 2011. We will do moderate share repurchases in the near term to offset option dilution primarily, but our real focus of cash in the near term is going to be on debt repayment, which we expect to be back in our target. That's at the top by mid-2013. So to your question on share count, we don't expect it necessarily to go down significantly. We were just going to try to manage a current balance as much as we can.
Combine this verification with a surging stock price, Stone Fox decided to sell the shares this morning. Taking advantage of a stock price that has soared from roughly $37 in mid December to $54 today.
The stock might go higher in the short term, but the new corporate focus of raising debt versus returning cash to shareholders is our signal to sell.
Details off the sell from Market Pulse:
Chart showing the extreme overbought condition. RSI above 90 and CCI above 220.
Disclosure: No positions mentioned. Please review the disclaimer page for more details.